Transaction DateRecipientSharesTypePriceValue
21st May 2020Omar Khwaja3,500Open or private sale$12.96$45,360.00
3rd April 2020Robert W. Hesslein3,091Open or private sale$8.51$26,304.41
10th February 2020Omar Khwaja30,000Grant/award etc.$0.00
10th February 2020Andre Turenne81,250Grant/award etc.$0.00
10th February 2020Robert W. Hesslein27,500Grant/award etc.$0.00
10th February 2020Allison Dorval27,500Grant/award etc.$0.00
21st January 2020Matthew P. Ottmer3,724Open or private sale$13.36$49,752.64
21st January 2020Andre Turenne10,705Open or private sale$13.36$143,018.80
21st January 2020Allison Dorval3,128Open or private sale$13.36$41,790.08
20th May 2019Omar Khwaja30,000Grant/award etc.$0.00
Voyager Therapeutics
Voyager Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.


Ticker: VYGR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1640266
Employees: 185
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $144 M (0%)
Marketable Securities, Current: $85 M (-56%)
Assets, Current: $247 M (-19%)
Property, Plant and Equipment, Net: $20 M (12%)
Assets: $297 M (-16%)
Accounts Payable, Current: $2 M (-49%)
Accrued Liabilities, Current: $18 M (0%)
Liabilities, Current: $68 M (-11%)
Other Liabilities, Noncurrent: $30 M (0%)
Liabilities: $221 M (-13%)
Common Stock, Value, Issued: $37 Th (0%)
Common Stock, Shares, Issued: $37 M (0%)
Retained Earnings (Accumulated Deficit): $346 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $145 Th (39%)
Stockholders' Equity (Parent): $77 M (0%)
Liabilities and Equity: $297 M (-16%)
Revenue: $29 M (-38%)
Research and Development: $29 M (-52%)
General and Administrative Expenses: $8 M (-55%)
Operating Income/Loss: $9 M (-73%)
Other Income, net: $300 Th (-36%)
EPS (basic): $0.23 (-74%)
EPS (diluted): $0.23 (-74%)